Printer Friendly

BIOJECT OPENS SOUTHWEST SALES REGION FOR NEEDLE-FREE INJECTOR

 PORTLAND, Ore., Feb. 24 /PRNewswire/ -- Bioject (NASDAQ: BJCT) announced today that it has begun sales of its Biojector(R) 2000, an advanced needle-free injection management system in the southwestern United States. Heading up the southwest sales effort is W. Cameron Hack, area field sales manager, who is based in Spring, Texas, outside of Houston.
 Hack, who joined Bioject on Feb. 22, has 20 years of medical device sales and marketing experience. He was most recently with Baxter International where he built and managed a start-up division of Caremark, exceeding revenue projections for the first two years by 150 and 200 percent, respectively.
 Hack's experience in healthcare also includes sales and marketing positions at HMSS Inc., Johnson & Johnson, Terumo Corp. and William Rorer Inc.
 The Biojector 2000 delivers commonly injectable drugs intramuscularly or subcutaneously without using a needle to penetrate patient skin. Because no contaminated needles are produced as a result of the injection process, the device eliminates the possibility of dangerous needlestick injuries.
 Needlestick injuries can transmit bloodborne pathogens, such as the HIV and hepatitis viruses, and now threaten the health of more than 12 million U.S. healthcare workers daily. Almost 1 million needlesticks are reported each year and it is believed that 60 percent more go unreported.
 In addition to its initial direct sales effort, Bioject has secured a Japan distribution arrangement with Kobayashi Pharmaceutical Co. for product distribution in Japan which is anticipated to begin later this year. It is also developing new products for the insulin market under a joint development agreement with Eli Lilly.
 Bioject was founded in 1985 to develop needle-free injection systems and today is the acknowledged leader in jet injection technology.
 -0- 2/24/93
 /CONTACT: Dan Zenka or Tim Justice of Bioject, 503-639-7221/
 (BJCT)


CO: Bioject Inc. ST: Oregon IN: MTC SU: PER

LM-SW -- SE008 -- 9952 02/24/93 13:35 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 24, 1993
Words:311
Previous Article:JLG INDUSTRIES REPORTS IMPROVED RESULTS FOR ITS SECOND QUARTER AND SIX MONTHS
Next Article:JOHN K. LEE AND ROBERT B. LOUTHAN RESIGN FROM EVEREX BOARD
Topics:


Related Articles
BIOJECT EXPANDS PRODUCT DISTRIBUTION WITH NATIONAL NETWORK
BIOJECT ANNOUNCES RESULTS FOR THIRD QUARTER FISCAL 1994
BIOJECT PRODUCT SALES INCREASE IN FISCAL 1995
BIOJECT ANNOUNCES PRIVATE PLACEMENT
BIOJECT REPORTS THIRD QUARTER RESULTS AND SUSPENSION OF HMI SHIPMENTS
BIOJECT AND SCHERING AG, GERMANY, SIGN SUPPLY AGREEMENT FOR BETASERON(R) INJECTION SYSTEMS
Bioject Announces Cancellation of Contract With Schering AG
Bioject Reports Improved Fiscal 1997 Performance
Bioject Enters Vaccine Agreement With Merck

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters